Literature DB >> 15766939

The efficacy of valnemulin (Econor) in the control of disease caused by experimental infection of calves with Mycoplasma bovis.

L Stipkovits1, P H Ripley, M Tenk, R Glávits, T Molnár, L Fodor.   

Abstract

Mycoplasma bovis infection was experimentally induced in groups of six young calves. A further group was uninfected and served as a control. Ten days after infection, medication with either enrofloxacin (Baytril, Bayer) or valnemulin (Econor, Novartis) was instituted via the milk replacer for a further 10 days, after which all calves were killed. Infection resulted in depression, pyrexia, inappetance and prominent respiratory signs. Arthritis occurred in two animals and two (unmedicated) animals died. At post-mortem examination extensive lesions were present in the lungs and M. bovis was re-isolated from infected unmedicated calves' lungs. Medication with either enrofloxacin or valnemulin resulted in a rapid diminution of clinical signs, restoration of appetite and reversal of weight loss. Isolation of Pasteurella multocida from the calves' lungs was suppressed by both medicaments. Valnemulin resulted in a more rapid reduction of clinical scores and eliminated M. bovis from the lungs more effectively than enrofloxacin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766939     DOI: 10.1016/j.rvsc.2004.09.005

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  15 in total

1.  Mutations Associated with Decreased Susceptibility to Seven Antimicrobial Families in Field and Laboratory-Derived Mycoplasma bovis Strains.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Enikő Wehmann; Inna Lysnyansky; Krisztián Bányai; Szilvia Marton; Ákos Jerzsele; Zsuzsanna Rónai; Ibolya Turcsányi; László Makrai; Szilárd Jánosi; Sára Ágnes Nagy; Miklós Gyuranecz
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 2.  The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.

Authors:  Michelle F Richter; Paul J Hergenrother
Journal:  Ann N Y Acad Sci       Date:  2018-02-15       Impact factor: 5.691

3.  A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii.

Authors:  Shajila Siricilla; Katsuhiko Mitachi; Junshu Yang; Shakiba Eslamimehr; Maddie R Lemieux; Bernd Meibohm; Yinduo Ji; Michio Kurosu
Journal:  J Med Chem       Date:  2017-03-22       Impact factor: 7.446

4.  Relationship between Antimicrobial Susceptibility and Multilocus Sequence Type of Mycoplasma bovis Isolates and Development of a Method for Rapid Detection of Point Mutations Involved in Decreased Susceptibility to Macrolides, Lincosamides, Tetracyclines, and Spectinomycin.

Authors:  Eiji Hata; Takehiro Harada; Megumi Itoh
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

5.  Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.

Authors:  Anne V Gautier-Bouchardon; Séverine Ferré; Dominique Le Grand; Agnès Paoli; Emilie Gay; François Poumarat
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

6.  In vitro and in vivo metabolite profiling of valnemulin using ultraperformance liquid chromatography-quadrupole/time-of-flight hybrid mass spectrometry.

Authors:  Shupeng Yang; Weimin Shi; Dingfei Hu; Suxia Zhang; Huiyan Zhang; Zhanhui Wang; Linli Cheng; Feifei Sun; Jianzhong Shen; Xingyuan Cao
Journal:  J Agric Food Chem       Date:  2014-09-02       Impact factor: 5.279

7.  Heterologous expression reveals the biosynthesis of the antibiotic pleuromutilin and generates bioactive semi-synthetic derivatives.

Authors:  Fabrizio Alberti; Khairunisa Khairudin; Edith Rodriguez Venegas; Jonathan A Davies; Patrick M Hayes; Christine L Willis; Andy M Bailey; Gary D Foster
Journal:  Nat Commun       Date:  2017-11-28       Impact factor: 14.919

8.  An antimycobacterial pleuromutilin analogue effective against dormant bacilli.

Authors:  Maddie R Lemieux; Shajila Siricilla; Katsuhiko Mitachi; Shakiba Eslamimehr; Yuehong Wang; Dong Yang; Jeffrey D Pressly; Ying Kong; Frank Park; Scott G Franzblau; Michio Kurosu
Journal:  Bioorg Med Chem       Date:  2018-08-18       Impact factor: 3.641

9.  In Vitro and In Vivo Activity of 14-O-[(4,6-Diamino-pyrimidine-2-yl) thioacetyl] Mutilin against Methicillin-Resistant Staphylococcus aureus.

Authors:  Yunxing Fu; Chunqing Leng; Yuan Fan; Xia Ma; Xianghui Li; Xuefei Wang; Zhenghuan Guo; Xiujun Wang; Ruofeng Shang
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

Review 10.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.

Authors:  Inna Lysnyansky; Roger D Ayling
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.